Industry Pulse

Views & Analysis

5-years-of-biosimilars-in-the-US-Industry-Pulse

5 years of biosimilars in the US: what have we learned?

Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.

Views & Analysis

Who could replace Sir Andrew Dillon at NICE?

With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks